BridgeBio Pharma, Inc. 宣布,公司拟于2026年下半年与相关监管机构举行会议,旨在讨论其候选药物Infigratinib的新药申请(NDA)及上市许可申请(MAA)的提交计划。
BridgeBio Pharma, Inc. 宣布,公司拟于2026年下半年与相关监管机构举行会议,旨在讨论其候选药物Infigratinib的新药申请(NDA)及上市许可申请(MAA)的提交计划。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.